Home health tech market expected to more than quadruple by 2020

The home health technology market is expected to grow to more than four times its current size by 2020, according to a report from market intelligence firm Tractica.

In 2014, approximately 14.3 million individuals worldwide were utilizing home health technologies. That number is expected to increase to 78.5 million by 2020, according to the Tractica report. Tractica anticipates that medical monitoring, diagnosis and treatment will be the largest application market during that timeframe and will drive the deployment of a wide variety of connected health devices and software applications. Other key segments of this market are remote consultations, eldercare and health and wellness.

Key drivers of the growth of the home health technology market include rising healthcare costs, the aging population and an increase in people with chronic conditions, according to Tractica analyst Charul Vyas. "However, significant challenges remain for the industry to solve, including regulatory issues, data security and privacy and technology interoperability and integration issues," said Vyas in a release.

 

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.